These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30186837)

  • 21. Pharmacokinetic study of Ninjin'yoeito: Absorption and brain distribution of Ninjin'yoeito ingredients in mice.
    Matsumoto T; Takiyama M; Sakamoto T; Kaifuchi N; Watanabe J; Takahashi Y; Setou M
    J Ethnopharmacol; 2021 Oct; 279():114332. PubMed ID: 34129897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of Ninjin'yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial.
    Yagi T; Sawada K; Miyamoto M; Kinose Y; Nakagawa S; Takiuchi T; Kodama M; Kobayashi E; Hashimoto K; Mabuchi S; Tomimatsu T; Yoshino K; Kimura T
    BMC Womens Health; 2022 Jun; 22(1):229. PubMed ID: 35701778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective.
    Matsela LM; Cleary S; Wilkinson T
    Cost Eff Resour Alloc; 2022 Dec; 20(1):69. PubMed ID: 36510230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.
    Alegre A; Vicuña I; Aguado B
    Clin Med Insights Oncol; 2012; 6():1-10. PubMed ID: 22253550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low frequency of CD3
    Lee SE; Lim JY; Ryu DB; Kim TW; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
    Ann Hematol; 2018 Nov; 97(11):2163-2171. PubMed ID: 29938309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India.
    Sashidharan N; Shenoy S; Kishore MK; Thanusubramanian H
    J Clin Diagn Res; 2015 May; 9(5):XC01-XC04. PubMed ID: 26155545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ninjin'yoeito Improves Genitourinary Symptoms in Patients With Frailty.
    Okui N; Okui MA
    Cureus; 2023 Jun; 15(6):e40767. PubMed ID: 37363115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
    Touzeau C; Blin N; Clavert A; Roland V; Loirat M; Tessoulin B; Le Gouill S; Planche L; Pennetier M; Mahe B; Mohty M; Malard F; Peterlin P; Dubruille V; Moreau P
    Leuk Lymphoma; 2012 Jul; 53(7):1318-20. PubMed ID: 22211836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
    Maisnar V; Stefanikova Z; Spicka I; Pour L; Minarik J; Flochova E; Radocha J; Gregora E; Stecova N; Jelinek T; Jungova A; Kralikova E; Brozova L; Hajek R
    Neoplasma; 2019 May; 66(3):499-505. PubMed ID: 30784289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
    Alegre A; Oriol-Rocafiguera A; Garcia-Larana J; Mateos MV; Sureda A; Martinez-Chamorro C; Cibeira MT; Aguado B; Knight R; Rosettani B
    Leuk Lymphoma; 2012 Sep; 53(9):1714-21. PubMed ID: 22292853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
    Sato H; Nakamura Y; Oi N; Namba K; Taniguchi Y; Yahata H; Komori H; Kobayashi H
    Gan To Kagaku Ryoho; 2015 Dec; 42(13):2461-6. PubMed ID: 26809305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of Ninjin'yoeito for Chronic Obstructive Pulmonary Disease Patients with Frailty.
    Hirai K; Homma T; Matsunaga T; Akimoto K; Yamamoto S; Suganuma H; Kashima A; Sato H; Ebato T; Miyata Y; Ohta S; Inoue H; Kusumoto S; Suzuki S; Tanaka A; Sagara H
    J Altern Complement Med; 2020 Aug; 26(8):750-757. PubMed ID: 32551796
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of Effect of Ninjin'yoeito on Regional Brain Glucose Metabolism by
    Zhao J; Imai R; Ukon N; Shimoyama S; Tan C; Maejima Y; Omiya Y; Takahashi K; Nan G; Zhao S; Ito H; Shimomura K
    Front Nutr; 2021; 8():657663. PubMed ID: 34055854
    [No Abstract]   [Full Text] [Related]  

  • 39. Liver Injury by the Traditional Chinese Medicine Hanshirento, Zenshikunshito, and Ninjin'yoeito in a Patient with Lung Cancer: Probable Causality Assessed by the Updated Roussel Uclaf Causality Assessment Method.
    Funakoshi H; Momo K; Kashima A; Ida H; Miyata Y; Sagara H; Sasaki T
    Integr Cancer Ther; 2021; 20():15347354211004734. PubMed ID: 33769124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Successful treatment with a combination of elotuzumab, lenalidomide and dexamethasone of extramedullary disease in a patient with refractory multiple myeloma].
    Kashima E; Fujieda A; Nato Y; Ino K; Tawara I; Masuya M; Katayama N
    Rinsho Ketsueki; 2020; 61(3):223-227. PubMed ID: 32224581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.